Suppr超能文献

华南地区一家三甲癌症中心的肛门鳞癌综合治疗经验。

Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China.

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, PR China.

Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.

出版信息

Cancer Med. 2022 Jan;11(1):117-127. doi: 10.1002/cam4.4433. Epub 2021 Nov 24.

Abstract

BACKGROUND

Anal squamous cell carcinoma (ASCC) is a rare malignant tumor with increasing incidence. The goal of our study was to analyze the treatment outcome and prognostic factors of ASCC in South China in the past half-century.

METHODS

This study retrospectively included 59 patients with ASCC admitted from 1975 to 2018 in Sun Yat-sen University cancer center. The clinical records and follow-up information of all patients were collected. Survival analysis and univariate and multivariate regression analyses were performed using the "survival" and "survminer" packages of R software.

RESULTS

In 59 patients, 5 patients had distant metastasis at diagnosis. Among 54 M0 stage patients, 33 patients received chemoradiotherapy (CRT), 19 patients received local surgery, and 2 patients refused curative treatment and received the best supportive treatment (BST). The most common grade 3-4 acute toxicities during treatment were myelosuppression and radiation dermatitis. The median follow-up time was 32 months. For the whole group, the 3-year and 5-year overall survival (OS) rates and disease-free survival (DFS) were 71.1% and 63.6%, and 73.4% and 69.0%, respectively. Multivariate regression analysis showed that the T3-4 stage was an independent prognostic risk factor for OS, progression-free survival (PFS), and DFS. And M1 was an independent prognostic risk factor for PFS and DFS. Patients in stage M0 mainly treated with CRT had better local control than those mainly treated with surgery (p = 0.027). For M0 patients, induction chemotherapy combined with CRT tends to prolong OS compared with CRT alone (p = 0.26). The 3-year colostomy-free survival for the whole group was 81.1%.

CONCLUSIONS

CRT is recommended as the first choice for the treatment of M0 stage ASCC. Induction chemotherapy may bring better survival benefits for some patients. Patients with ASCC in China seem to have a better local control rate, which suggested different treatment strategies may be needed in China.

摘要

背景

肛门鳞状细胞癌(ASCC)是一种罕见的恶性肿瘤,发病率呈上升趋势。本研究旨在分析过去半个世纪中国南方 ASCC 的治疗结果和预后因素。

方法

本研究回顾性纳入中山大学肿瘤防治中心 1975 年至 2018 年收治的 59 例 ASCC 患者。收集所有患者的临床记录和随访信息。采用 R 软件“survival”和“survminer”包进行生存分析和单因素及多因素回归分析。

结果

在 59 例患者中,5 例患者在诊断时即发生远处转移。在 54 例 M0 期患者中,33 例接受放化疗(CRT),19 例接受局部手术,2 例拒绝根治性治疗,给予最佳支持治疗(BST)。治疗过程中最常见的 3-4 级急性毒性是骨髓抑制和放射性皮炎。中位随访时间为 32 个月。全组患者 3 年和 5 年总生存率(OS)和无病生存率(DFS)分别为 71.1%和 63.6%、73.4%和 69.0%。多因素回归分析显示,T3-4 期是 OS、无进展生存(PFS)和 DFS 的独立预后危险因素。M1 期是 PFS 和 DFS 的独立预后危险因素。主要接受 CRT 治疗的 M0 期患者局部控制率优于主要接受手术治疗的患者(p=0.027)。对于 M0 期患者,诱导化疗联合 CRT 与单纯 CRT 相比,OS 延长(p=0.26)。全组 3 年无造口生存为 81.1%。

结论

CRT 是 M0 期 ASCC 的首选治疗方法。诱导化疗可能会给部分患者带来更好的生存获益。中国 ASCC 患者的局部控制率似乎更高,这提示中国可能需要不同的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e999/8704146/db786eadea54/CAM4-11-117-g003.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验